ibudilast

More importantly, your management team continues to misunderstand the value of our offer, which is that Avigen shareholders will have an opportunity to receive up to an estimated 45\% of the MediciNova common stock (on a post-conversion basis) and thereby share in the synergies associated with combining our two different and non-competitive therapeutic indications for ibudilast.

News 2009

More importantly, your management team continues to misunderstand the value of our offer, which is that Avigen shareholders will have an opportunity to receive up to an estimated 45\% of the MediciNova common stock (on a post-conversion basis) and thereby share in the synergies associated with combining our two different and non-competitive therapeutic indications for ibudilast.

News 2009

More importantly, your management team continues to misunderstand the value of our offer, which is that Avigen shareholders will have an opportunity to receive up to an estimated 45\% of the MediciNova common stock (on a post-conversion basis) and thereby share in the synergies associated with combining our two different and non-competitive therapeutic indications for ibudilast.

News 2009

However, in Tuesday's letter from your CEO, Ken Chahine very much surprised us when he wrote to say that our mutually - agreed approach to handling the ibudilast due diligence will place us at a disadvantage to other bidders in the auction process and that your CEO is no longer prepared to abide by the due diligence protocol that we thought we had agreed.

News 2009

However, in Tuesday's letter from your CEO, Ken Chahine very much surprised us when he wrote to say that our mutually - agreed approach to handling the ibudilast due diligence will place us at a disadvantage to other bidders in the auction process and that your CEO is no longer prepared to abide by the due diligence protocol that we thought we had agreed.

News 2009

However, in Tuesday's letter from your CEO, Ken Chahine very much surprised us when he wrote to say that our mutually - agreed approach to handling the ibudilast due diligence will place us at a disadvantage to other bidders in the auction process and that your CEO is no longer prepared to abide by the due diligence protocol that we thought we had agreed.

News 2009

Inc. (Nasdaq: AVGN - News), a biopharmaceutical company, today announced that they have confirmed their understanding of certain key terms for a proposed acquisition of Avigen by MediciNova that would combine the companies 'broad neurological clinical development programs based on ibudilast (Avigen's AV-411 and MediciNova's MN-166).

SeekingAlpha.com: Home Page 2009

MediciNova's failure to execute strategic plans or strategies successfully, MediciNova's collaborations with third parties, MediciNova's ability to realize the anticipated strategic and financial benefits from its acquisition of Avigen, Inc., to integrate the two ibudilast development programs and to pursue discussions with potential partners to secure a strategic collaboration to advance the clinical development of the combined development program, the availability of funds to complete product development plans and MediciNova's ability to raise sufficient capital when needed, intellectual property or contract rights, and the other risks and uncertainties described in MediciNova's filings with the Securities and Exchange

News 2010

As you hopefully have been told, we previously agreed with your management team to execute a confidentiality agreement without a standstill arrangement and proceed with staged due diligence, with the mutual understanding that we would share with one another certain sensitive data regarding ibudilast (which, as you are aware, is in clinical development by both parties for different therapeutic indications) only at the end of our negotiation process if we were in broad agreement on the parameters of a deal.

News 2009

As you hopefully have been told, we previously agreed with your management team to execute a confidentiality agreement without a standstill arrangement and proceed with staged due diligence, with the mutual understanding that we would share with one another certain sensitive data regarding ibudilast (which, as you are aware, is in clinical development by both parties for different therapeutic indications) only at the end of our negotiation process if we were in broad agreement on the parameters of a deal.

News 2009